The company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.

Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...

TOLEDO — A 42-year-old man was arrested after he allegedly threatened a person with a loaded gun inside an Ohio restaurant on Friday, according to WTOL-11 and WTVG-13. Matthew Exon, 42 ...

Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, ...

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

As explained in their conference abstract, HG302 is a one-time single-cut CRISPR-Cas12 therapy that is designed to induce exon skipping and restore dystrophin expression with minimal off-target ...